Furthermore, the Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) study which was a multicentre, double-blind, placebo-controlled randomized clinical trial of patients with established HF and reduced LVEF has demonstrated that liraglutide does not improve post-hospitalization clinical stability in patients with advanced HF and reduced LVEF despite prior studies indicating that GLP-1 therapy might ameliorate mechanisms of myocardial insulin resistance reported in patients with severe cardiomyopathies (108). Here, GLP1R is linked to heart failure.